KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Halozyme Therapeutics (HALO) over the last 15 years, with Dec 2024 value amounting to $80.6 million.

  • Halozyme Therapeutics' Other Non-Current Assets fell 30.51% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 30.51%. This contributed to the annual value of $80.6 million for FY2024, which is 352.38% up from last year.
  • As of FY2024, Halozyme Therapeutics' Other Non-Current Assets stood at $80.6 million, which was up 352.38% from $17.8 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Other Non-Current Assets high stood at $80.6 million for FY2024, and its period low was $13.4 million during FY2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $26.3 million (2022), whereas its average is $41.6 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Other Non-Current Assets slumped by 32.26% in 2023 and then spiked by 352.38% in 2024.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Other Non-Current Assets stood at $14.1 million in 2020, then fell by 4.64% to $13.4 million in 2021, then soared by 96.07% to $26.3 million in 2022, then tumbled by 32.26% to $17.8 million in 2023, then skyrocketed by 352.38% to $80.6 million in 2024.